This study is in progress, not accepting new patients
CY 6031 Study Will Evaluate the Effects of Treatment With Aficamten (CK-3773274) Over a 24-week Period on Cardiopulmonary Exercise Capacity and Health Status in Patients With Symptomatic oHCM
Summary
- Eligibility
- for people ages 18-85 (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Cytokinetics
- ID
- NCT05186818
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- About 282 people participating
- Last Updated